Clinical Trial Search

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 3; 4; 5; 7 Participants

Primary: Number of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) — 3; 4; 6; 2 Participants

Primary: Time to Maximum Concentration (Tmax) of Erenumab — 7.0; 7.0; 9.0; 7.0 days

Primary: Safety of Treatment With High-titer Anti-SARS-CoV-2 Plasma as Assessed by Adverse Events — 0 Participants

Primary: Total Body Muscle Mass — 21.8; 20.8; 22.2; 20.8 kg units on a scale

Primary: Single Rising Dose (SRD): Percentage of Subjects With Drug-related Adverse Events. — 0.0; 11.1; 0.0; 0.0 Percentage of participants

Primary: Adverse Event of Special Interest (AESIs) and Adverse Events (AEs) Leading to Discontinuation — 0; 0; 1; 2 adverse events

Primary: Number of Deaths Due to Adverse Events (AEs) — 1; 0 Participants

Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 2; 2; 4; 6 Participants

Primary: Number of Participants With Dose-limiting Toxicities (DLT) — 0 Participants

Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 1, Per Common Terminology Criteria for Adverse Events (AEs), Version 5.0 (CTCAE) — 2…

Primary: Part 1: Cmax After the First and Last Dose — 1.59; 7.70; 9.87; 18.0 microgram (µg)/ millilitre (mL)

Primary: Maximum Observed Concentration (Cmax) of PF-06480605 — 41530 nanogram per milliliter (ng/mL)

Primary: Maximum Observed Plasma Nicotine Concentration (Cmax) of NicoDerm CQ Dungarvan (Test) Compared to NicoDerm CQ, Alza (Reference) — 23.554; 24.478 Nanograms per milliliter…

Primary: Incidence and Severity of Treatment-emergent Adverse Events (TEAEs) — 4; 3; 2; 3 Participants